Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Ipilimumab/nivolumab

Various toxicities: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sinha K, et al. Combination Nivolumab and Ipilimumab therapy related Diabetic Ketoacidosis: an imperative to support glycemic monitoring during therapy. Journal of the American Geriatrics Society 71 (Suppl. 1): S109, Apr 2023. Available from: URL: http://doi.org/10.1111/jgs.18336 [abstract] Sinha K, et al. Combination Nivolumab and Ipilimumab therapy related Diabetic Ketoacidosis: an imperative to support glycemic monitoring during therapy. Journal of the American Geriatrics Society 71 (Suppl. 1): S109, Apr 2023. Available from: URL: http://​doi.​org/​10.​1111/​jgs.​18336 [abstract]
Metadaten
Titel
Ipilimumab/nivolumab
Various toxicities: case report
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-42800-0

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Isoniazid

Case report

Sulphan-blue

Case report

Tofacitinib

Case report

Methotrexate

Case report

Decitabine